Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis

Yoodee, Jukapun; Permsuwan, Unchalee; Nimworapan, Mantiwee

doi:10.1016/j.critrevonc.2017.02.017

Cited by 50 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We agree that severe QTc prolongation is not an acute risk with olanzapine monotherapy in children without other cardiac risk factors or QTc prolonging polypharmacy. However, in clinical oncology practice, many children are on concomitant QTc prolonging medications and may need a reference electrocardiogram, often available from their baseline medical work‐up . In terms of dosing, we agree that 0.1 mg/kg/dose (max: 10 mg/dose) is a reasonable rule of thumb, though dosage forms of oral and disintegrating tablets may limit the increments for dosing.…”

mentioning

confidence: 83%

Reply to: Comment on: Olanzapine for chemotherapy‐induced nausea: Lessons learned from child and adolescent psychiatry

Samsel

Kearney

Meadows

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

mentioning

confidence: 83%

Reply to: Comment on: Olanzapine for chemotherapy‐induced nausea: Lessons learned from child and adolescent psychiatry

Samsel

Kearney

Meadows

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

“…Одним из наиболее заметных нежелательных эффектов оланзапина является седация, которая может снижать приверженность пациентов к терапии и создавать неудобства при проведении лечения, особенно -в амбулаторном режиме. По данным метаанализа [29], около 35% пациентов при применении оланзапина испытывают седацию/повышенную сонливость. Навари Р. М.…”

Section: краткие данные о профиле безопасности оланзапинаunclassified

Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting

et al. 2018

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) has tremendous negative impact on daily life of cancer patients and their quality of life. In this article we analyzed current clinical guidelines in preventive measures and treatment of CINV as well as efficacy of recommended standard regimens for CINV prevention in patients receiving high emetogenic chemotherapy (HEC). We summarized existing data about olanzapine – affordable antipsychotic agent with potent antiemetogenic activity which is quite useful for CINV prophylaxis in patients receiving HEC. We highlighted possible future directions for research of olanzapine in oncology and reasons that preclude integration of this drug in routine clinical practice in Russia.

show abstract

“…Olanzapine, an antipsychotic agent, blocks multiple neurotransmitters: serotonin, at 5H2a, 5H2c, 5H3, and 5HT6 receptors, dopamine at D1, D2, D3, and D4 brain receptor, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors. 7 In previous studies, olanzapine has been demonstrated to be a safe and effective agent in improving cancer-related symptoms, including chemotherapy-induced nausea and vomiting (CINV), [7][8][9][10][11][12][13][14][15][16] cancer pain, 17,18 cancer-related anorexia, 19,20 and cachexia. 21 The efficacy of olanzapine in improving HRQoL of cancer patients was demonstrated in several studies as a secondary endpoint.…”

mentioning

confidence: 99%

Efficacy of olanzapine for quality of life improvement among patients with malignant tumor: A systematic review

Cui

et al. 2019

Cancer Reports

View full text Add to dashboard Cite

Background Cancer patients always experience an ongoing deterioration in health‐related quality of life (HRQoL). There is a strengthening awareness of health care professionals of taking HRQoL, which is a patient‐reported outcome measures (PROMs), into consideration when they make an adequate selection in clinical practice. Olanzapine, an antipsychotic agent, has been demonstrated to be a safe and effective agent in improving cancer‐related symptoms. Aim To review the efficacy and safety of olanzapine in improving HRQoL among adults with malignant tumor. Methods Eligible studies were retrieved from an electronic database search of the Cochrane, Medline, CINAHL plus, Pubmed, Embase, PsycINFO, Web of Science, and Scopus. The methodological quality of selected studies was evaluated, and the relevant data were extracted and synthesized. Results While studies differed in target population, olanzapine‐based treatment regimen, and HRQoL measurement tools, results have shown that olanzapine has a positive impact on cancer patients' general HRQoL status, functional outcomes, and/or symptoms improvement. Besides, no serious toxicities attributable to olanzapine were observed in all studies included. Conclusion While further studies are needed especially which adopted the HRQoL as primary outcome through comprehensive measures, olanzapine could still be recommended in the palliative care.

show abstract

Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis

Cited by 50 publications

References 32 publications

Reply to: Comment on: Olanzapine for chemotherapy‐induced nausea: Lessons learned from child and adolescent psychiatry

Reply to: Comment on: Olanzapine for chemotherapy‐induced nausea: Lessons learned from child and adolescent psychiatry

Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting

Efficacy of olanzapine for quality of life improvement among patients with malignant tumor: A systematic review

Contact Info

Product

Resources

About